Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
34.2K
-
Shares change
-
-17.4K
-
Total reported value, excl. options
-
$301K
-
Value change
-
-$202K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$8.79
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2023
2 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2023.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.2K shares
of 105M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include Capital World Investors (11.9M shares), BlackRock Inc. (7.45M shares), Palo Alto Investors LP (5.24M shares), VANGUARD GROUP INC (5.07M shares), FRANKLIN RESOURCES INC (4.75M shares), JPMORGAN CHASE & CO (4.64M shares), Polar Capital Holdings Plc (3.17M shares), STATE STREET CORP (2.52M shares), GEODE CAPITAL MANAGEMENT, LLC (1.92M shares), and Invesco Ltd. (1.6M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.